ECE2013 Poster Presentations Neuroendocrinology (42 abstracts)
Evaluation of the efficacy of midnight salivary cortisol plus dexamethasone suppression test as screening for the diagnosis of hypercortisolism within an at-risk population
Alfonso Leal-Cerro 1 , Ainara Madrazo-Atutxa 1 , Juan Garcia-Arnes 1 , Cristina Lamas-Oliveira 1 , Mauro Boronat-Cort 1 , Juan A Lillo 1 , Carmen Fajardo 1 , Eulalia Urgell-Rull 2 , Javier Salvador 1 , Isabel Salinas 1 , Ignacio Bernabeu 1 , Concha Paramo 1 , Susan Webb 1 , Elena Torres-Vela 1 , Angel Diaz 1 , Javier Aller 1 & Antonio Leon-Justel 2
1Department of Endocrinology and Nutrition, Instituto de Biomedicina de Sevilla (IBIS), Virgen del Rocio University Hospital, Seville, Spain; 2Department of Clinical Biochemistry, Barcelona, Spain.
Introduction: Endogenous Cushing’s syndrome (CS) is a rare, infradiagnosed and severe disease that carries high morbidity and mortality. Delays in treatment initiation reduce reversibility of symptoms and increase mortality rate. Current gold standard for screening, 24 h urinary free cortisol, has a low reproducibility and specificity, and sampling is complicated. Midnight salivary cortisol (MSVC) determination is considered an easy and cheap test. We intend to assess its feasibility combined with suppression test to screen CS. This initiative has been developed by the Cushing’s disease (CD) working group, member of the Sociedad Española de Endocrinología y Nutrición (SEEN) and supported by Novartis.
Methods/design: Epidemiological cross-sectional study to asses MSVC plus suppression test. Secondary objectives are to describe the prevalence of CS and CD in the studied population. Patients will be performed the two tests, results from both, clinical characteristics and final diagnosis of CS or CD will be recorded.
Results: This project, named CRIbado en SALIva De Alteraciones del cortisol (CRISÁLIDA) was initiated on November 2012, with 13 participating sites accross Spain. Sample size will be 609 patients and results from an interim analysis are expected on April 2013. Study population includes a group of patients considered at risk of presenting high cortisol levels, presenting at least 2 of the following symptoms: obesity (BMI >30), hard to control hypertension (SBP >140 and DBP >90 mmHg, >2 drugs), poorly controlled diabetes (HbA1c >7.0%), severe osteoporosis (−2.5 S.D. in T-score) or virilization syndrome. Exclusion criteria: pregnancy, age >70 years, glucocorticoid treatment, CS or CD diagnosis, chronic renal impairment or hepatopathy, between others.
Conclusion: CRISÁLIDA is a multicentric project designed to identify most relevant characteristics of an at-risk population and to move forward in the screening and diagnosis of a rare disease (CD).
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more